Books > Medicine > General issues > Public health & preventive medicine > Epidemiology & medical statistics
|
Buy Now
Statistical Approaches in Oncology Clinical Development - Current Paradigm and Methodological Advancement (Hardcover)
Loot Price: R4,109
Discovery Miles 41 090
|
|
Statistical Approaches in Oncology Clinical Development - Current Paradigm and Methodological Advancement (Hardcover)
Series: Chapman & Hall/CRC Biostatistics Series
Expected to ship within 12 - 17 working days
|
Statistical Approaches in Oncology Clinical Development : Current
Paradigm and Methodological Advancement presents an overview of
statistical considerations in oncology clinical trials, both early
and late phase of development. It illustrates how novel statistical
methods can enrich the design and analysis of modern oncology
trials. The authors include many relevant real life examples from
the pharmaceutical industry and academia based on their first-hand
experience. Along with relevant references, the book highlights
current regulatory views. The book covers all aspects of cancer
clinical trial starting from early phase development. The early
part of the book covers novel phase I dose escalation design,
exposure response analysis, and innovative phase II design. This
includes early development strategy for cancer immunotherapy
trials. The contributors also emphasized the role of biomarker and
modern era of precision medicine. The second part focuses on the
late stage development. This includes the application of adaptive
design, safety analysis, and quality of life (QoL) data analysis.
The final part discusses current regulatory perspective and
challenges. Features: Covers a wide spectrum of topics related to
real-life statistical challenges in oncology clinical trials.
Provides a comprehensive overview of novel statistical methods to
improve trial design and statistical analysis. Detailed case
studies illustrate the real life applications. Satrajit
Roychoudhury is a Senior Director and a member of the Statistical
Research and Innovation group in Pfizer Inc. Prior to joining; he
was a member of Statistical Methodology and consulting group in
Novartis. He has 11 years of extensive experience in working with
different phases of clinical trial. His area of research includes
early phase oncology trials, survival analysis, model informed drug
development, and use of Bayesian methods in clinical trials. He is
industry co-chair for the ASA Biopharmaceutical Section
Regulatory-Industry Workshop and has provided statistical training
in major conferences including the Joint Statistical Meetings, ASA
Biopharmaceutical Section Regulatory-Industry Workshop, and ICSA
Applied Statistics Symposium. Soumi Lahiri has 12 years of
extensive experience in working different therapeutic areas. She is
the former Director of Biostatistics in Clinical Oncology,
GlaxoSmithKline. She has also worked in the oncology division of
Novartis Pharmaceutical Company for two years. She is an active
member of the ASA Biopharmaceutical section and former chair of the
membership committee.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.